MorphoSys (MOR)
(Delayed Data from NSDQ)
$17.89 USD
+0.02 (0.11%)
Updated May 3, 2024 04:00 PM ET
After-Market: $17.91 +0.02 (0.11%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.89 USD
+0.02 (0.11%)
Updated May 3, 2024 04:00 PM ET
After-Market: $17.91 +0.02 (0.11%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Zacks News
4 Lucrative Stocks With Amazingly High Net Income Ratio
by Nitish Marwah
Profitability analysis is considered one of the best possible ways to assess the prospects of a company.
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Incyte, MorphoSys Application for Lymphoma Drug Validated
by Zacks Equity Research
Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues
by Zacks Equity Research
Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.
MorphoSys BLA for Cancer Drug Gets Priority Review from FDA
by Zacks Equity Research
MorphoSys (MOR) BLA for blood cancer drug gets Priority Review from the FDA.